![]() ![]() ![]() In addition to internal research and development activities, Bayer Schering Pharma is also involved in publicly funded collaborative research projects, with other industrial and academic partners. Through Bayer Healthcare AG, Bayer Schering Pharma is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). ![]() Schering's best-known product is their line of combined oral contraceptive pills. The company focuses on the business areas of gynaecology and andrology, oncology, and also special therapeutics, diagnostical devices, and nuclear medicine. They retain the largest German manufacturing facility which is located in Bergkamen. The company's headquarters are in Berlin-Wedding, Germany and the forerunner company Schering's annual gross revenue was nearly € 5 billion (2003). The company employs more than 26,000 people in 140 subsidiaries all over the world. The company was originally founded in 1851 by Ernst Christian Friedrich Schering (1824-1869). Current multiples based on per-share metrics (such as earnings per share or book value per share) are calculated using the last closing price, while current multiples based on company-level metrics (such as net sales, EBIT or EBITDA) are calculated using the current market cap or EV (Enterprise Value).Bayer Schering Pharma AG is a research-centered pharmaceutical company that was formed by the merger of Schering with Bayer on 29 December 2006. Current multiples include: - Historical multiples based on standardized financials for the last completed fiscal period: Last, Last Twelve Months (LTM) - Forward multiples based on consensus estimates for the current fiscal period and next ones: Next Twelve Months (NTM), FY0, FY1. Put simply, this method multiplies the sales or profits of a business by an industry averaged multiplier to calculate the Market Value of the business. The market valuation is utilized generally as a primary market input, to provide an objective starting point for the valuation. ![]() One of the most widely used quantitative methods is the market multiples method. In reality, business valuation is often a combination of these different approaches. Many methods can be used to value a company. The (current) company valuation of Bayer Schering Pharma AG is therefore way below its valuation average over the last five years. The N/A ratio of Bayer Schering Pharma AG is significantly lower than its historical 5-year average: N/A. The company valuation of Bayer Schering Pharma AG according to these metrics is way below the market valuation of its sector. The N/A ratio of Bayer Schering Pharma AG is significantly lower than the average of its sector (Pharmaceuticals): 7.47. The company valuation of Bayer Schering Pharma AG according to these metrics is way below the market valuation of its peer group. The N/A ratio of Bayer Schering Pharma AG is significantly lower than the median of its peer group: around 16.00. A company with a high N/A is considered to be overvalued a company with a low N/A is considered to be undervalued. This multiple is used to compare a company's market value with its earnings. P/E relates the current share price with the market expectations in terms of Earnings Per Share. The most common multiple used in the valuation of stocks is the N/A multiple (Price to Earnings). Market multiple valuation of Bayer Schering Pharma AG ( SCH | DEU) ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |